Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1118

VTX1218-hIgG4-S228P

Home » VTX1218-hIgG4-S228P

Background of VTX1218-hIgG4-S228P

VTX-1218, a monoclonal antibody (mAb), exhibits an affinity for VSIG4 (V-set and immunoglobulin domain containing 4), a type-I receptor belonging to the B7-like family. This receptor is notably abundant on tumor-associated macrophages and dendritic cells across various tumor types. VTX-1218 demonstrates the capability to repolarize macrophages into a pro-inflammatory state, thereby triggering T-cell activation and fostering the recruitment of other immune cells. This orchestrated response culminates in a potent antitumor effect. In contrast to VTX-0811, VTX-1218 modulates disparate molecular pathways governing macrophage biology and showcases distinct expression profiles across various immune cell subsets. Furthermore, it exhibits elevated target expression in numerous tumor types.

Specifications

Catalog Number:
KB-1118
Antibody Name:
VTX1218-hIgG4-S228P
Isotype:
Human IgG4-S228P, kappa
FC Muations:
S228P
Target:
VSIG4
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Liu B, Cheng L, Gao H, et al. The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer[J]. Cancer Letters, 2022: 215996.
  2. Ye Q, Liu J, Xie K. B7 Family proteins in cancer progression: Immunological and non-immunological functions[J]. Journal of Cancer Treatment and Diagnosis, 2019, 3(4).
  3. Amir Taghavi B, Alizadeh N, Saeedi H, et al. Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy[J]. Molecules, 2022, 27(11): 3545.